Patients are advised that tofacitinib may reduce the ability of their immune system in order to fight infections. Patients are advised not to initiate taking tofacitinib in case they have an active infection.
Patients are advised to contact their doctor as soon as possible while on tofacitinib 5 mg treatment in case symptoms suggesting infection occur to ensure the rapid evaluation as well as the appropriate treatment.
Patients are informed that tofacitinib may be responsible for increasing their risk of certain cancers, and that lymphoma and other cancers have been observed in patients taking tofacitinib. Patients are advised to inform their doctor in case they have ever had any sort of cancer.
Advise pregnant females about the reproductive potential of the potential risk to a fetus. Females are advised to notify their prescriber about known or suspected pregnancy.
Women are advised not to breastfeed during tofacitinib treatment and for at least 18 hours following the last tofacitinib dose or 36 hours after the last tofacitinib dose.
Patients taking tofacitinib may observe an inert tablet shell passing through stool or via colostomy. Patients are informed that the active medicine has already been absorbed by the time the patient notices the inert tablet shell.
top of page
Search
bottom of page